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1. INTRODUCTION 
1.1 The eye: embryogenesis 
Eye development begins around the 4th week of gestation and can be summarized in 
four main stages [Zagozewski J.L. et al.; 2014]:  
 Optic vesicle formation 
 Induction of crystalline lens 
 Retinal tissue formation 
 Optic fissure closure 
 
Each of these events is highly regulated and coordinated by various transcription factors 
and circulating molecules [Adler R. et al.; 2007]. The first morphological signs of eye 
development are two protrusions that form optic vesicle in the lateral walls of the 
prosencephalon. In this process, at a molecular level, an important role is played by the 
gene RAX, encoding for a protein that helps ectoderm cells migration and movement, 
inhibiting the expression of a cell-adhesion factor, Nicam [Bailey T.J. et al.; 2004]. The 
optic vesicles develop and infold to form the optic cups, which connect to the 
diencephalus via the optic peduncles. 
Meanwhile, the ectoderm, covering each optic cup, is organized to form the lens 
placode, which thicken giving rise to the crystalline lens. At this stage,  the gene PAX6 
is very important, because PAX6 protein, together with other transcription factors, such 
as SOX2, allows the synthesis of the proteins that will form the lens [Shaham O. et al.; 
2012]. In this process, optic cup and optic peduncle will form, respectively, retina and 
optic nerve and several genes are involved in this step, such as SHH and PAX2. SHH 
promotes the development of optical cup cells to retina. PAX2 is instead involved in the 
separation between the optic cup cells, which will be part of retinal epithelium, and the 
pedicle cells, which will form the axon outgoing from the ocular bulb [Chow R.L. et al.; 
2011]. At this stage, it is important that the distal portions of the optical cup cells (future 
retinal cells) come closer, thus allowing the closure of the optic fissure [Adler R. et al.; 
2007]. Morphogenesis of the eye is completed when the optic fissure is closed and 
retinal neurogenesis is ongoing. Once the formation of crystalline lens and retina is 
completed, the surrounding mesoderma completes the development, forming the 
choroid and the sclera [Barishak Y.R.; 1992]. 
 
1.2 MAC: Mixed group of diseases 
1.2.1 Microphthalmia, Anophthalmia and Coloboma 
Anophthalmia, microphthalmia (A/M) and coloboma are eye defects caused by 
disfunctions during the eye development [Ragge N.K. et al.; 2007]. The “anophthalmia” 
term is referred to a complete absence of the ocular globe even if the ocular annexes,  
such as conjunctiva and lacrimal apparatus, are present. The microphthalmia is a 
condition where the ocular globe, present in the orbit, is smaller than normal [Verma 
A.S. et al.; 2007 ; Plaisancie J. et al.; 2016]. The parameters used to define the size of 
eyeball are the corneal diameter and the total axial length (TAL),that represents the 
distance, in millimeters, from the cornea apex to the posterior part of the ocular bulb. 
Microphthalmia is classified in severe, simple and nano microphthalmia, based on the 
reduction of the total axial length. The most severe forms show a corneal diameter <4 
mm and a TAL <10 mm at birth, or <12 mm after the first year of age [Bardakjian T. et 
al.; 2004]. The term “Coloboma” is referred to ocular malformations that often match 
with microphthalmia and result from failure of closure of the optic fissure during the 
embryogenesis [Warburg M.; 1991]. It may involve several eye structures, as the iris, 
choroid, ciliary body, retina and optic nerve. The affected patients present consequences 
from mild to severe. If the embryonal defect involves only iris, the patient does not 
report any damage to the vision, but when the failure of closure of the optic fissure 
involves the optic nerve a more severe coloboma occurs [Cunliffe H.E. et al.; 1998]. 
These pathologies, enclosed under the acronym of MAC, can be found in isolated 
forms, with defects interesting exclusively the visual structure, or in syndromic forms, 
with  more complex pathological features. Some of the syndromic forms can show an 
anophthalmia associated to an esophageal and/or genital anomaly, anophthalmia 
combined to pituitary anomalies, microphthalmia associated to linear skin defects or 
anophthalmia associated to pituitary anomalies in the presence of polysindactily 
[Pasutto F. et al.; 2007 ; Williamson K.A. et al; 2014]. 
The combined presence of  these conditions is 30/100.000 births, and more detailed 
statistical studies show a range from 0.6 to 4.2 on 100,000 births for anophthalmia, from 
2 to 17 out of 100,000 births for microphthalmia and from 2 to 14 on 100,000 births for 
coloboma [Morrison D. et al.; 2002]. In addition, in the 11% of blind children is 
reported microphthalmia. Anophthalmia and microphthalmia have complex aetiology, 
with chromosomal, monogenic and enviromental causes identified. Chromosomal 
duplications, deletions and translocations are implicated [Williamson K.A. et al; 2014] 
and also environmental factors can play a role in the pathogenesis of the disease. The 
strongest evidence for the environmental influence appears to be associated to 
gestational-acquired infections, but may also include maternal vitamin A deficiency, 
exposure to X-rays, solvent abuse and thalidomide exposure [O'Keefe M. et al.; 1987]. 
Patients are often treated by multidisciplinary teams, including ophthalmologists, 
pediatricians and clinical geneticists, especially in syndromic cases. Diagnosis is based 
on clinical examination together to imaging diagnostic examinations, including A-scan 
ultrasonography, to measure total axial length, B-scan ultrasonography to measure the 
internal structures of the globe and computerized tomography scan (CT) or MRI 
(magnetic resonance imaging) of the brain and orbits to evaluate both the size and 
internal structures of the globe, as well as the optical nerves and the extraocular muscle 
structure [Albernaz V.S. et al.; 1997]. At a genetic level it is important the genetic 
counseling to identify the complete pathological picture and the family history, and, of 
course, the chromosome analysis and molecular genetic tests. Among the genes 
associated with MACs there are SHH, PAX6, PAX2, RAX, SOX2, GDF6, VSX2, 
OTX2, HCCS, BMP4. In anophthalmia or severe microphthalmia case, usually the two 
most frequently mutated genes are SOX2 and OTX2, respectively in 10% and 3% of 
cases [Schneider A. et al., 2009]. VSX2, PAX6, RAX, BMP4 and GDF6 mutations are 
more rare [Azuma N. et al.; 1999 ; Henderson R.A. et al; 2007]. Both clinical and 
experimental evidences suggest that these pathologies have a heterogeneous genetic 
basis. The resulting phenotypes share some clinical features, and this aspect reflects the 
complex network involved in organogenesis of the eye, where signal molecules, 
transcription factors, down regulation mechanisms of cell cycle components and the 
inhibition of cell-adhesion factors play an important role. 
 
1.2.2 Syndromic Diseases 
 CHARGE Syndrome 
CHARGE syndrome is characterized by a combination of phenotypic aspects, where the 
main features are enclosed in the acronym of its name: coloboma, heart malformation, 
atresia choanae (choanal atresia), growth retardation, genital abnormalities and ear 
abnormalities. Subsequently, other abnormalities have been added, such as dysmorphia, 
romboencephalus dysfunction, hypoplasia of semicircular channels and 
holoprosencephaly. CHARGE syndrome is a rare disease transmitted as an autosomal 
dominant tract and its prevalence is 1/10,000 births; its clinical diagnosis is established 
according to the diagnostic criteria delineated by Blake [Blake K.D. et al.; 2006]. One 
of the main criteria in order to diagnose CHARGE syndrome is to propose the co-
existence of coloboma and choanal atresia. Mutations in CHD7 gene are found in more 
than 70% of patients diagnosed with this syndrome [Lalani S.R. et al.; 2006]. CHD7 is 
located on chromosome 8 at position q12.1, it is a large gene (188 kb) which contains 
37 exons. Its protein product comprises 2997 amino acids; it belongs to the family of 
chromodomain helicase DNA-binding protein, which comprises 9 members (CHD1-
CHD9). CHD7 protein can form complexes with different proteins or can establish 
specific bonds with different regions of the genome, allowing temporal and specific-
tissue regulation of gene expression. Indeed, its action implies a modification of the 
chromatin structure, altering the accessibility of the transcription apparatus to DNA. Its 
role as a regulatory element explains the several phenotypic effects of its mutations 
[Pisaneschi E. et al.; 2015 ; Bergman J.E. et al.; 2011]. 
 
 
 Cornelia de Lange Syndrome 
Cornelia de Lange Syndrome is a clinically heterogeneous disease with an autosomal 
dominant mode of inheritance. Classic Cornelia de Lange syndrome (CdLS) is 
characterized by distinctive facial features, growth retardation (prenatal onset; <5th 
centile throughout life), hirsutism, and upper limb reduction defects that range from 
subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features 
include synophrys, highly arched eyebrows, long eyelashes, short nose with anteverted 
nares, small widely spaced teeth, and microcephaly. IQ ranges from below 30 to 102 
(mean: 53). Many patients demonstrate autistic and self-destructive tendencies. 
Frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing 
loss, myopia and cryptorchidism or hypoplastic genitalia [Deardorff M.A. et al.; 2005]. 
Individuals with a milder phenotype have less severe growth, cognitive, and limb 
involvement, but often have facial features similar to CdLS phenotype [Boyle MI et al.; 
2015].  
The prevalence of CdLS is difficult to estimate as individuals with milder features are 
likely under-recognized. Published estimates for the prevalence range from 1:100,000 
[Pearce P.M. et al.; 1967] to as high as 1:10,000 [Opitz J.M.; 1985]. More recent data 
from the EUROCAT dataset have estimated the prevalence at 1:50,000 for the classic 
form of CdLS [Barisic et al.; 2008].  
Diagnosis is based on clinical findings and/or the identification of a heterozygous 
pathogenic variant in NIPBL, RAD21, or SMC3 or a hemizyous pathogenic variant 
in HDAC8 or SMC1A [Mannini L et al.; 2013].  NIPBL gene encodes a highly 
conserved protein, also known as delangine, which performs functions such as DNA 
repair or transcription regulation, and is also involved in cohesin protein regulation. 
Cohesin is a protein complex, made up of four core subunits: SMC1A, SMC3, RAD21 
and STAG. This complex plays a key role in chromosome cohesion and segregation of 
sister chromatids. Recently, it has been confirmed that mutations in cohesin’s regulators 
and in structural components of the complex are responsible of Cornelia de Lange 
phenotype [Kaur M. et al; 2016]. Mutations in HDAC8 have also been associated to 
Cornelia de Lange syndrome [Feng L. et al.; 2014]. HDAC8 is an SMC3 deacetylase; 
loss of function mutations found in Cornelia de Lange patients result in an increased 
activity of acetylated SMC3 and an inadequate dissolution of cohesin during prophase 
and anaphase. HDAC8 mutations are rarer than those found in NIPBL gene, which 
involve 60% of individuals with Cornelia de Lange. The cohesin components, SMC1A 
and SMC3, are respectively mutated in 5% and 1% of patients affected by CDLS 
[Huisman S. et al.; 2017]. 
 
 Axenfeld-Rieger Syndrome 
Axenfeld-Rieger syndrome (ARS) is a rare autosomal dominant disorder with ocular 
anterior segment dysgenesis and systemic anomalies. The patients affected by this 
pathology can display different phenotypes. Clinical signs can be divided into two 
categories, ocular and non-ocular. Ocular abnormalities include hypoplasia of the iris, 
with formation of fissures similar to those found in polycoria and corectopia. The most 
frequent non-ocular signs are skull- facial dysmorphisms, teeth abnormalities, such as 
microdontia and hypodontia, redundancy of periombelic sk in and jaw hypoplasia. The 
prevalence of this syndrome is 1/200,000 births. [Song W. et al.; 2017]. Diagnosis is 
performed through ophthalmological and clinical examinations and is supported by 
genetic testing. Mutations in PITX2 and FOXC1 genes are often found in individuals 
with Axenfeld Rieger's syndrome. Both genes encode for transcription factors and 
approximately 40% of patients have mutations in one of the two genes. Generally 
PITX2 mutations are associated with ocular anomalies, teeth and umbilical 
abnormalities, while mutations in FOXC1 gene are reported in patients with isolated eye 
anomalies or whit eye, hearing and heart anomalies [Kelberman D. et al.; 2011]. 
 
 
 
 
 Lenz microphthalmia 
Lenz microphthalmia syndrome (LMS) is characterized by unilateral or 
bilateral microphthalmia and/or clinical anophthalmia with malformations of the ears, 
teeth, hands, skeleton, and urinary system. Microphthalmia is often accompanied by 
microcornea and glaucoma. Coloboma is present in approximately 60% of 
microphthalmic eyes with severity ranging from isolated iris coloboma to coloboma of 
the ciliary body, choroid and optic disk. Ears may be low set, anteverted, posteriorly 
rotated, simple, cup shaped, or abnormally modeled [Ng D.; 2002]. Hearing loss has 
been observed. Dental findings include irregularly shaped, missing, or widely spaced 
teeth. Duplicated thumbs, syndactyly, clinodactyly, camptodactyly, and microcephaly 
are common, as are narrow/sloping shoulders, underdeveloped clavicles, 
kyphoscoliosis, exaggerated lumbar lordosis, long cylindric thorax, and webbed neck. 
Genitourinary anomalies include hypospadias, cryptorchidism, renal hypoplasia/aplasia, 
and hydroureter. Approximately 60% of affected males have mild-to-severe intellectual 
disability or developmental delay. The diagnosis of Lenz microphthalmia syndrome is 
based on clinical findings. Mild simple microphthalmia can be identified by measuring 
the axial length of the globe with A-scan ultrasonography. NAA10 (MCOPS1 locus) 
and BCOR (MCOPS2 locus) are the only two genes known to be associated 
with Lenz microphthalmia syndrome (LMS) [Hilton et al.; 2009]. 
 
 Papillorenal syndrome 
Renal coloboma (papillorenal syndrome) is an autosomal dominant condition 
characterized by renal hypodysplasia and abnormalities of the optic nerve. Abnormal 
renal structure or function is noted in 92% of affected individuals; ophthalmologic 
abnormalities are observed in 77% of affected individuals who have pathogenic variants 
in PAX2, that encodes a transcription factor involved in the first stages of eye 
development. Renal abnormalities can be clinically silent in rare individuals. In most 
individuals, clinically significant renal insufficiency/renal failure is reported. End-stage 
renal disease requiring renal transplant is not uncommon. Ophthalmologic abnormalities 
are typically described as optic nerve coloboma or dysplasia [Bower M.A. et al.; 2007]. 
Iris colobomas have not been reported in any individual with a PAX2 pathogenic 
variant. Ophthalmologic abnormalities may significantly impair vision in some 
individuals, while others have subtle changes only noted after detailed ophthalmologic 
examination. Additional clinical findings include hearing loss, which is noted in 7% of 
individuals with identified pathogenic variants in PAX2. The prevalence of renal 
coloboma syndrome is unknown. More than 180 affected individuals with pathogenic 
variants have been reported worldwide. The number of individuals without pathogenic 
variants who have classic findings of renal coloboma syndrome is not known. There is 
no evidence for a significant founder effect in any population [Bower M. et al.; 2012]. A 
case of papillorenal syndrome was also described in the literature due to a translocation 
of the PAX2 gene, t(2; 15)(q31; q26) [Aydin B. et al.; 2013]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Molecular diagnosis: Next Generation Sequencing 
The term “genome” was invented in 1920 by geneticist Hans Winkler; it indicates an 
hybrid between "gene" and "chromosome" and it refers to the genetic information of an 
organism contained in its DNA sequence. If a DNA is mutated, genetic information may 
be altered and proteins may no longer be produced in a functional manner. Some 
mutations are associated to diseases, while others cause phenotypic variations. These 
mutations, and the information included in human genome can be studied in several 
different ways and at different levels [Lewis R., 2010]. In a mendelian or monogenic 
disease, by performing a genetic analysis of the single causative gene it is possible to 
obtain a sure diagnosis. When the clinical picture is more complex, it is recommended 
to investigate a wide range of genes which may be involved in the phenotype. In this 
diagnostic perspective it is useful to develop a technique able to perform an high-
throughput gene sequencing in order to find the causative mutation of the pathologic 
condition.  
DNA sequencing is a process that elaborates the order of the nucleotides of a  genomic 
DNA fragment. In 1977 Fred Sanger and his colleagues developed an approach based 
on high-fidelity DNA replication which was obtained using a DNA polymerase and 
dideoxynucleotides [Sanger F. et al., 1977]. This concept has provided the base for the 
development of automated systems based on Sanger sequencing. Sanger sequencing, 
also known as first-generation sequencing, has been spread all over the world since the 
1980's and has been the method chosen for over 25 years. The big limits of the Sanger 
method are linked to time, cost and resolution. It is still used to confirm the sequence 
variants, but Next Generation Sequencing (NGS) is now being widely used for large-
scale DNA analysis. NGS, unlike conventional Sanger sequencing, allows the 
sequencing of many fragments in parallel [Rehm H.L. et al.; 2013]. Several NGS 
systems have been developed by different companies. All these systems, however, have 
three main steps: DNA preparation and immobilization (“sequence library 
preparation”), amplification reaction and sequencing reaction.  
The introduction of this efficient technology is a step forward in the field of sequencing 
with great advantages in the comprehension of human genetics and diseases. The 
possibility to analyze millions of sequencing reactions in parallel at very reduced costs, 
with shorter processing times and very little amounts of initial DNA, has provided a 
formidable boost for the study of rare diseases. [Glenn T.C.; 2011]. The pathologies that 
benefited the most from NGS are mainly complex syndromes caused by many 
mutations in different genes, such as anophthalmia and microphthalmia, which can now 
be diagnosed in shorter times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. AIM OF THE STUDY 
In these last few years, both mendelian and complex diseases have reached a higher 
level of accuracy in the analytical process, with a more efficient diagnostic definition 
and also a more detailed genotype-phenotype correlation. Complex syndromic 
pathologies, as microphthalmia and anophthalmia, often accompanied by complex 
clinical pictures, and characterized by a high level of genetic and phenotypic 
heterogeneity, can now be handled in a faster and thorough manner. 
The aim of this project was to carefully investigate the genes involved in 
microphthalmia, anophthalmia, coloboma and related syndromic diseases using Next 
Generation Sequencing. This new molecular approach allows to make a massive 
sequencing of different genomic regions.  
In the present study, a panel of different genes involved in the ocular development has 
been developed to test and analyze simultaneously and rapidly multiple ocular genes of 
a patient by using the Illumina-Nextseq 500. The method also allows the simultaneous 
analysis of multiple patients. Each mutation found was confirmed using the classic 
Sanger sequencing. This analytical approach supports the clinical evaluation in genetic 
counseling with molecular results, providing a broader spectrum of the genetic 
background of a patient that can help in the definition of complex phenotypes. 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
3.1 Patients recruitment 
 Casuistry 
The cases included in the present study have been recruited among patients’samples 
belonging to the Medical Genetics Laboratory Unit of the “Ospedale Pediatrico Bambin 
Gesù” in Rome, from October 2014 to October 2016. During the third year of this PhD 
project, the results of the analysis performed on the samples previously recruited were 
elaborated. The ethnic distribution of selected patients reflects that of the general 
population, mainly Caucasian in origin from the italian territory. A total of 134 patients 
were included in the study group, including 41 with microphthalmia/anophthalmia, 34 
with CHARGE syndrome, 37 with Cornelia de Lange syndrome and a total of 22 
patients with combined diagnosis of Rieger syndrome, Lenz microphthalmia and 
papillorenal syndrome.  
 Ethical evaluation 
This study and each activity has been performed in accordance to the protocol of the 
Helsinki Declaration. The study required the use of human biological material, in 
particular peripheral blood taken from patients with microphthalmia, anophthalmia and 
coloboma or rare syndromes in which the ocular defect is associated to other clinical 
features. Both preventive and operational procedures relating to this project have been 
addressed to the principles of the Universal Declaration of Bioethics and Human Rights 
adopted unanimously in 2005 by UNESCO member countries. In addition, a "prior, 
free, explicit and informed consent of the person involved" was obtained by eac h 
subject included in the study or by both parents if the proband was underage at the time 
of blood sampling, as guaranteed by the Italian ordinance and in accordance to Art. 6 of 
the Universal Declaration of Bioethics and Human Rights and also in accordance to the 
"a" and "d" paragraphs of article 6 of the International Declaration on Human Genetic 
Data. In case of physical or mental impairment of a patient, unable to give his informed 
consent, the subscription was obtained by the legal tutor. Finally, in accordance to art. 9 
"the privacy of the people involved and the confidentiality of their personal data" has 
been respected. The laboratory has implemented the principles of "Good Laboratory 
Practices" for the safety of operators and personnel involved, both for the use of 
chemical reagents and for the handling of biological materials and derived products, 
with the aim of avoiding the risk of species-specific transmission of viral and not-viral 
pathogens. We acted according to the principles contained in art. 20 of the Universal 
Declaration of Bioethics and Human Rights ("Risk Assessment and Management") for 
an appropriate assessment and proper risk management, minimizing the possibility of 
error and managing the risk probability with appropriate procedures. The operator 
behavior was inspired to art.18 of the Universal Declaration of Bioethics and Human 
Rights. We acted following the criteria of "professionalism, honesty, integrity and 
transparency". We also declare that there were no conflicts of interest.  
 
3.2 Molecular Analysis 
3.2.1 Blood collection, DNA extraction and quantification 
 Blood collection 
After filling the informed consent the patients underwent blood sampling (5 ml of 
venous blood, in test tubes containing EDTA). The samples were then recorded, 
associated to a barcode and carefully stored at -20 ° C. 
 DNA Extraction 
DNA extraction by peripheral blood lymphocytes was performed through “QIAamp 
DNA Blood Mini Kit” (Qiagen). This protocol is based on three main steps: a 
purification step, in which DNA is absorbed for affinity on in silico columns, a series of 
washing steps with appropriate buffers to eliminate RNA and proteins, and an elution 
step to collect purified genomic DNA. In detail, 20 μ l of 15.1mg/μ l proteinase K 
solution (600AU/ml) and 200 μ l of lysis buffer (AL) are added to 200 μ l of blood. An 
incubation phase at 56°C for 10' follows, to allow the lysis of white blood cells. The 
cellular lysis causes the leakage of nuclear DNA by dissociation of membrane 
phospholipids and hydrolysis of cytoplasmic proteins. After the incubation phase at 
56°C, 200 μ l of 100% ethanol are added. The resulting solution is transferred in a small 
column containing a silica membrane with high affinity for DNA. The column is then 
centrifuged at 8000 rpm for 1’. After centrifugation, the columns are placed on new 
tubes and the filtrate is discarded. After the addition of 500 μ l of buffer AW1 (wash 
buffer 1), used to wash the column filters, a centrifugation at 8000 rpm for 1' is 
performed. The flowthrough is then removed and the samples are washed with 500 μ l of 
AW2 buffer (wash buffer 2) and centrifuged at 14,000 rpm for 3 min. After placing the 
columns on new 1.5 ml eppendorf collection tubes, the genomic DNA ligated to the 
filter is eluted with DNAse free water. This procedure was performed both manually 
and robotically using Qiagen automatic extractors (QiaCube and QiaSymphony).  
 DNA quantification 
DNA was quantified both by NanoDrop 1000 spectrophotometer (ThermoScientific) 
and by PicoDrop fluorometer (PicoDrop Technology). In spectrophotometric 
measurements, in addition to the concentration value, it is possible to obtain the ratio 
between the two optical densities (O.D.260nm / O.D.280nm), which represent a 
measure of the purity of the extracted sample. Values ranging from 1.8 to 2.0 are 
representative of high quality samples. An additional analysis to verify the 
concentration of DNA samples was made using FLx800 Fluorescence Microplate 
Reader with the graphic support of  BioTek's Gen5TM 2.0 Data Analysis software. The 
fluorescence signal was obtained using the Quant- iTTM PicoGreen kit, a highly sensitive 
fluorescent dye, useful for double-helix DNA quantification (dsDNA). While methods 
based on absorbance measurement detect, in addition to dsDNA, also contaminants such 
as nucleotides, single-stranded nucleic acids, RNAs and proteins, highlighting 
interferences in data measurement, dyes such as PicoGreen Hoechst (Bisbenzimide) 
bypass many of these problems. The PicoGreen® reagent comes in a concentrated 
anhydrous dimethylsulfoxide (DMSO) solution. A 1:200 dilution of PicoGreen® was 
prepared using a 2X solution with 1X TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). 
After creating a calibration curve with standard DNA, the extracted DNA is diluted 
1:100 with 1X TE, in a final volume of 100 μ l, to which an equal amount of diluted 
solution of 2X PicoGreen® Reagent is added. The solution is incubated for 5 minutes 
protected from light, as the reagent is photosensitive, and then transferred on the plate 
for analysis with fluorimeter. DNA thus obtained is stored at -20° C, with an average 
concentration of 25ng/μ l. 
3.2.2 NGS panel construction: DesignStudio 
Next Generation Sequencing offers the possibility to make the sequencing of multiple 
genes in a single experiment. Once the genes to include have been chosen, the 
appropriate primers or specific probes complementary to the target genomic regions are 
designed. DesignStudio is an on line software provided by Illumina that, through 
different bioinformatic tools, allows the optimal construction of the amplicons or the 
oligonucleotide probes complementary to the genomic region of interest (target). The 
algorithms in the software work to define a series of factors useful to optimize the panel 
construction. For example, information on the presence of GC-rich regions, on the 
specificity of the oligonucleotide probes or on the coverage are obtained. In order to 
maximize the amplification reaction, optimal size ranges of the amplicons are chosen 
depending on the starting material, e.g. tissue included in paraffin or blood. Illumina 
also offers a variety of analytical approach methods, which may involve the use of 
amplicons or probes, providing different types of chemistry of genomic sequencing, 
such as Truseq Custom Amplicon (TSCA) kits or Nextera kits Rapid Capture Custom 
Enrichment. However, the specific technique is chosen according to the laboratory 
needs. In our laboratory, Nextera kits have been chosen based on probes targeting our 
genomic regions of interest. After oligonucleotide probes design, panel realization is 
confirmed and in a short time, about 40 days, the reagent kit is obtained. During a 
NextSeq run, fragments of the target regions are sequenced. Two different panels were 
developed over time. The first panel designed included all A/M genes, including also 
those involved in syndromic conditions (Fig. 1). Subsequently, in order to enhance the 
experiments performance we decided to design two different panels, one comprising 
only the A/M genes, and the other with genes involved in syndromic pathologies 
(Fig.2). 
 
Fig.1 First panel designed comprising MAC and syndromic d iseases  
GENES Chromosome 
Position 
Exons 
 
Mut. 
Freq. 
A/D Phenotypic Characteristic /Syndromes 
PAX6 Chr11:31,806,290 – 
31,839,559 
16  D aniridia, anophthalmia 
SOX2 Chr3:181,429,672 – 
181,432,273 
1 (4) 10-
20% 
D A/M (Microphthalmia, syndromic3) 
OTX2 Chr14:57,267,375 – 
57,277,234 
7 3,3-8% D A/M, pituitary abnormalities (microphthalmia, syndromic  
5) 
VSX2 Chr14:74,706,125 – 
74,729,491 
5 2% R Microphthalmia, cataract, coloboma (microphthalmia, 
isolated 2)(microphthalmia with coloboma 3) 
GDF6  Chr8:97,154,508 – 
97,173,070 
2 8% D A/M, coloboma (microphthalmia, isolated 4) 
SHH Chr7:155,595,508 – 
155,605,017 
3  D Colobomatous microphthalmia, anophthalmia, 
(holoprosencephaly 3)(microphthalmia with coloboma 5) 
RAX Chr18:56,934,217 – 
56,940,675 
3 2% R Anophthalmia, microphthalmia (microphthalmia, isolated 
3) 
PAX2 Chr10:102,505,418 – 
102,589,745 
13  D Papillorenal syndrome 
BCOR ChrX:39,910,449 – 
40,036,632 
17  X-R Lenz microphthalmia syndrome 
(oculofaciocardiodental)(microphthalmia, syndromic 2) 
CHD7 Chr8:61,591,289 – 
61,779,515 
38  D CHARGE syndrome (microphthalmia, coloboma) 
NIPBL  Chr5:36,676,811 – 
37,065,971 
48 50% D Cornelia de Lange syndrome 
SMC3  Chr10:112,327,399 – 
112,364,442 
29 2,50% D Cornelia de Lange syndrome 
SMC1A ChrX:53,401,020 – 
53,449,668 
25 2,50% X-D Cornelia de Lange syndrome 
HDAC8  ChrX:71,549,316 – 
71,793,003 
14  X-R Cornelia de Lange syndrome 
RAD21  Chr8:117,858,123 – 
117,887,155 
14  X-R Cornelia de Lange syndrome 
NDP ChrX:43,807,974 – 
43,832,971 
3  X-R Norrie disease 
HCCS ChrX:11,129,356 – 
11,141,254 
9  X-D MIDAS: microphthalmia,dermal aplasia and sclerocornea 
(microphthalmia, syndromic 7) 
PITX2 Chr4:111,538,530 – 
111,558,558 
6  D Rieger syndrome 
FOXC1 Chr6:1,610,631 – 
1,614,179 
1  D Rieger syndrome 
ERCC6  Chr10:50,664,441 – 
50,747,197 
21  R Cerebrooculofacioskeletal syndrome 1 
SIX6  Chr14:60,975,888 -
60,978,575  
2  D Microphthalmia, cataract, nystagmus (microphthalmia 
with cataract 2) 
HESX1 Chr3:57,231,894 – 
57,234,330 
4  D Septooptic dysplasia 
SIX3  Chr2:45,168,987 – 
45,173,266 
2  D Microphthalmia, coloboma, PHPV (holoprosencephaly 2) 
STRA6 Chr15:74,471,758 – 
74,502,096 
26  R Matthew-Wood syndrome/PDAC syndrome 
(microphthalmia, syndromic 9)(microphthalmia, isolated, 
with coloboma 8) 
MFRP Chr11:119,209,602 – 
119,217,433 
15  R microphthalmia, isolated 5(nanophthalmos) 
GDF3  Chr12:7,842,331 – 
7,848,410 
2  D Microphthalmia, isolated 7 
FOXE3  Chr1:47,881,694 – 
47,883,774 
1  R/D Cataracts, glaucoma 
CRYBA4  Chr22:27,017,878 – 
27,026,656 
6  D Microphthalmia 
BMP4  Chr14:54,416,405 – 
54,423,604 
6  D A/M; r (microphthalmia, syndromic 6) 
RSK3 Chr6:166,822,853 – 
167,275,770 
21    
Fig.2 Development of two different panels: one for MAC genes (Fig 2a); the other for syndromic 
pathologies (Fig 2b) 
2a   
GENES Chromosome 
Position 
Exons 
 
Mut. 
Freq. 
A/D Phenotypic Characteristic /Syndromes 
PAX6 Chr11:31,806,290 – 
31,839,559 
16  D aniridia, anophthalmia 
SOX2 Chr3:181,429,672 – 
181,432,273 
1 (4) 10-
20% 
D A/M (Microphthalmia, syndromic3) 
OTX2 Chr14:57,267,375 – 
57,277,234 
7 3,3-8% D A/M, pituitary abnormalities (microphthalmia, 
syndromic  5) 
VSX2 Chr14:74,706,125 – 
74,729,491 
5 2% R Microphthalmia, cataract, coloboma 
(microphthalmia, isolated 2)(microphthalmia with 
coloboma 3) 
GDF6  Chr8:97,154,508 – 
97,173,070 
2 8% D A/M, coloboma (microphthalmia, isolated 4) 
SHH Chr7:155,595,508 – 
155,605,017 
3  D Colobomatous microphthalmia, anophthalmia, 
(holoprosencephaly 3)(microphthalmia with 
coloboma 5) 
RAX Chr18:56,934,217 – 
56,940,675 
3 2% R Anophthalmia, microphthalmia (microphthalmia, 
isolated 3) 
SIX6  Chr14:60,975,888 -
60,978,575  
2  D Microphthalmia, cataract, nystagmus 
(microphthalmia with cataract 2) 
HESX1 Chr3:57,231,894 – 
57,234,330 
4  D Septooptic dysplasia 
SIX3  Chr2:45,168,987 – 
45,173,266 
2  D Microphthalmia, coloboma, PHPV 
(holoprosencephaly 2) 
STRA6 Chr15:74,471,758 – 
74,502,096 
26  R Matthew-Wood syndrome/PDAC syndrome 
(microphthalmia, syndromic 9)(microphthalmia, 
isolated, with coloboma 8) 
MFRP Chr11:119,209,602 – 
119,217,433 
15  R microphthalmia, isolated 5(nanophthalmos) 
GDF3  Chr12:7,842,331 – 
7,848,410 
2  D Microphthalmia, isolated 7 
FOXE3  Chr1:47,881,694 – 
47,883,774 
1  R/D Cataracts, glaucoma 
CRYBA4  Chr22:27,017,878 – 
27,026,656 
6  D Microphthalmia 
BMP4  Chr14:54,416,405 – 
54,423,604 
6  D A/M; r (microphthalmia, syndromic 6) 
RSK3/RPS6KA2 Chr6:166,822,853 – 
167,275,770 
21    
 
2b 
GENES Chromosome 
Position 
Exons 
 
Mut. 
Freq. 
A/D Phenotypic Characteristic /Syndromes 
PAX2 Chr10:102,505,418 – 
102,589,745 
13  D Papillorenal syndrome 
BCOR ChrX:39,910,449 – 
40,036,632 
17  X-R Lenz microphthalmia syndrome 
(oculofaciocardiodental)(microphthalmia, syndromic 2) 
CHD7  Chr8:61,591,289 – 
61,779,515 
38  D CHARGE syndrome (microphthalmia, coloboma) 
NIPBL  Chr5:36,676,811 – 
37,065,971 
48 50% D Cornelia de Lange syndrome 
SMC3 Chr10:112,327,399 – 
112,364,442 
29 2,50% D Cornelia de Lange syndrome 
SMC1A ChrX:53,401,020 – 
53,449,668 
25 2,50% X-D Cornelia de Lange syndrome 
HDAC8  ChrX:71,549,316 – 
71,793,003 
14  X-R Cornelia de Lange syndrome 
RAD21  Chr8:117,858,123 – 
117,887,155 
14  X-R Cornelia de Lange syndrome 
NDP ChrX:43,807,974 – 
43,832,971 
3  X-R Norrie disease 
HCCS ChrX:11,129,356 – 
11,141,254 
9  X-D MIDAS: microphthalmia,dermal aplasia and sclerocornea 
(microphthalmia, syndromic 7) 
PITX2 Chr4:111,538,530 – 
111,558,558 
6  D Rieger syndrome 
FOXC1 Chr6:1,610,631 – 
1,614,179 
1  D Rieger syndrome 
ERCC6  Chr10:50,664,441 – 
50,747,197 
21  R Cerebrooculofacioskeletal syndrome 1 
OCRL ChrX:128,674,252 – 
128,726,530 
24  X-R Oculocerebrorenal syndrome (Lowe) 
 
3.2.3 NextSeq-500: features and workflow 
 
The Illumina NextSeq 500 system combines the power of high- throughput sequencing 
with the simplicity of a desktop sequencer. Its fast, integrated, sample-to-result 
workflow enables rapid sequencing of exomes, whole genomes, targeted panels, 
transcriptomes in a single run, with the flexibility to switch to lower-throughput as 
needed. It also supports “Truseq” and “Nextera” library kits. Flow cells are available in 
configurations for high output and mid output. Each flow cell type is kitted with a 
compatible prefilled reagent cartridge. Integrated analysis software performs on-
instrument data analysis, which includes image analysis and base calling. The NextSeq 
uses an implementation of Real-Time Analysis (RTA) called RTA v2, which includes 
important architecture and feature difference. The sequencing workflow is integrated 
with BaseSpace, the Illumina genomics computing environment for data analysis, 
storage, and collaboration. For instrument configured for BaseSpace, library 
information and run parameters are specified on the BaseSpace Prep Tab. Runs that 
were set up in BaseSpace appear on the instrument interface during run setup. As the 
run progresses, output files are streamed in real time to BaseSpace or BaseSpace Onsite. 
The NextSeq Series enables researchers to keep pace with technology, putting them in 
control of their sequencing projects. The flexible NextSeq Series enables researchers to 
switch quickly from one application to another and configure output based on sample 
volume and coverage needs. Now, even the smallest laboratory can perform any 
combination of sequencing applications to advance their studies, supporting faster 
publication of landmark research. [https://support.illumina.com/content/dam/illumina-
support/documents/documentation/system_documentation/nextseq/nextseq-500-system-
guide-15046563-02.pdf] 
  
 
 Libraries preparation: Nextera Rapid Capture Custom Enrichment 
 
Nextera Rapid Capture Custom Enrichment is an all- in-one assay for library preparation 
and custom target enrichment. Nextera tagmentation coupled with optimized target 
capture ensures the fastest enrichment workflow time for custom content. The flexible, 
fully customizable design accommodates up to 15 Mb of custom content so you can 
focus on the regions of the genome that you care about. Nextera-based library 
preparation generates adapter-tagged libraries from 50 ng input genomic DNA. Nextera 
tagmentation of DNA simultaneously fragments and tags DNA without the need for 
mechanical shearing, using the Nextera transposone that bind tightly to DNA ends, 
fragmenting and tagging DNA with adapter sequences in a single step, adding by PCR 
step Index 1 (i7) and Index 2 (i5), the common adapters required for cluster generation 
and sequencing. Integrated sample barcodes allow the pooling of up to 12 of these 
adapter ligated sample libraries into a single, hybridization-based, pulldown reaction 
(Fig. 3A). The pooled libraries are then denatured into single-stranded DNA (Fig. 3B) 
and biotin- labeled probes complementary to the targeted region are used for the Rapid 
Capture hybridization (Fig. 3C). Streptavidin beads are added, which bind to the 
biotinylated probes that are hybridized to the targeted regions of interest (Fig. 3D). 
Magnetic pulldown of the streptavidin beads enriches the targeted regions that are 
hybridized to biotinylated probes. (Fig. 3E). The enriched DNA fragments are then 
eluted from the beads and a second round of Rapid Capture is completed to increase 
enrichment specificity.  
The entire process is completed in only 1.5 days, enabling a single researcher to process 
up to 12 samples efficiently and at one time all without automation 
[https://www.illumina.com/content/dam/illuminamarketing/documents/products/datashe
ets/datasheet_nextera_rapid_capture_custom_enrichment.pdf].  
 
 
 Fig. 3 Nextera Rapid Costum Workflow 
 
 Cluster generation 
To perform a sequencing run on the NextSeq 500 we have to insert the reagent cartdrige 
and a flow cell in the instrument. Flow cell is a glass-based substrate on which clusters 
are generated and the sequencing reaction is performed. The flow cell is made of a thin 
channel divided in tiles. Inside the tiles are linked some oligonucleotides, 
complementary to adapters P5 and P7, which are bound to the end of the sequencing 
templates.  Thanks to the hybridization of the adapters with flow cell oligonucleotides, 
template stability is guaranteed on the support. Subsequently, libraries are amplified on 
the surface of this special slide, through a reaction called bridge amplification (Fig. 4). 
This step allows the amplification of up to 1000 identical copies of each molecule 
enclosed in a cluster, in a space of 1 micron.  
      
 Fig. 4 Cluster generation through Bridge amplificat ion  
 
 Sequencing  
Illumina sequencing methodology is defined Sequencing By Synthesis (SBS). Base 
readings are made in real time. Each sequencing cycle has four steps: incorporation, 
fluorescence, image and washing (Fig. 5). The four nucleotides are labeled with 
different fluorocromes, making image capturing possible. Unlike Sanger method, where 
labeled nucleotides block the binding of the next nucleotide, those used in sequencing 
by synthesis allow the extension of the new filament. These nucleotides, represented by 
3'_O_Ozydomethyl molecules, reproduce reversible terminators. Following the 
incorporation of a complementary base in the strand of new synthesis, the molecule is 
excited by the laser and a light signal is registered as image to identify the added base. 
Subsequently, the 3'OH of the modified nucleotide is restored in order to be able to 
accommodate a new base. This reaction occurs simultaneously for all filaments 
anchored within the flow cell and the images are collected independently for each 
incorporation. The running performance can be followed in real time using the 
Sequencing Analysis Viewer (SAV) software. This software provides information on 
the number and quality of the clusters generated and on the general performance of the 
experiment. 
 Fig. 5 Sequencing by synthesis 
 
3.2.4 Sanger Sequencing 
All mutations found with Next Generation Sequencing have been confirmed by 
traditional Sanger sequencing, which is also used to analyze genomic regions not 
covered by NGS sequencing. 
  
 Acquisition of genomic sequences 
Coding sequences of genes included in our study have been obtained from online 
genetic banks, as the Santa Cruz California University Web site (UCSC Genome 
Bioinformatics- http://genome.ucsc.edu/). 
 Primers design  
Primers were designed to obtain a maximum amplified length of about 500 bp. For this 
purpose the Primer3 online software  was used, allowing oligonucleotide choice based 
on the annealing temperature and length. Once a potential pair of primers has been 
processed by the program, its specificity for the genomic region of interest was checked 
using Primer BLAST (NCBI) database and SNPcheck online software is interrogated in 
order to avoid the presence of  SNPs in the primer sequences  
 
 Polymerase chain reaction (PCR)  
For each PCR reaction about 50ng of genomic DNA, 1pmol/μ l of each specific primer 
for the target sequence, 0,175mM of dNTPs, dimethyl sulfoxide (DMSO) in appropriate 
quantities, 0,025 unit/μ l of DNA Polymerase Kapa Fast (Kapabiosystem, Wilmington, 
USA) and 1X reaction buffer (Kapa2G Buffer A with Mg) were used. Amplification 
reactions were performed on Veriti Thermal Cycler (Applied Biosystems). With this 
type of thermocycler it is possible to amplify samples at different temperatures in the 
same experiment. This is useful to evaluate the success of the reaction at different 
annealing temperatures in the same session. PCR reactions start with an enzymatic 
activation step at 95°C for 1' followed by 30 cycles of: denaturation step at 95°C for 10', 
annealing step at a specific temperature for each primer pair for 10'' and extension step 
at 72°C for 1''. A final extension at 72°C for 30' ends the reaction. 
  
 PCR purification 
All components that are not incorporated in the amplification reaction such as salts, 
primers or primer dimers that may subsequently interfere with the sequencing reaction, 
are removed by an enzymatic purification with Illustra ExoproSTAR method (GE 
Healthcare Life Sciences). This reagent is composed by two hydrolytic enzymes, an 
exonuclease I (EXO I), which eliminates primers in excess and single-stranded DNA, 
and an alkaline phosphatase (Shrimp Alkaline Phosphatase) that removes dNTPs not 
incorporated in the PCR reaction hydrolyzing them in nucleosides and inorganic 
phosphate. 4 μ l of PCR product and 1 μ l of ExoproSTAR enzyme are added in a PCR 
tube and inserted in the thermocycler with the following program:  
 37°C for 15' (enzymatic activation) 
 80°C for 15' (enzymatic inactivation)  
 
 Sequencing reaction 
Purified PCR products can now be sequenced. In Sanger sequencing the sequence is 
generated through the formation of fragments of different sizes exploiting a controlled 
interruption of the enzymatic replication. Together with the four deoxyribonucleotides 
triphosphate (dATP, dTTP, dCTP, dGTP), 2',3'-dideoxynucleotides of each base 
(ddATP, ddTTP, ddCTP, ddGTP), labeled with different fluorochromes,  are added to 
purified PCR products allowing the extension of the strand based on the amplified 
template strand. When the dideoxynucleotides are randomly incorporated in the 
sequence of new synthesis the elongation is interrupted, as the modified nucleotides 
miss the hydroxyl terminal 3', essential to form the next phosphodiester linkage. 
Fragments of different lengths with labeled 3’ ends are hence casually generated. 
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystem) is used for 
sequencing reaction. Two different reactions are prepared for each primer, forward and 
reverse. Each mix is composed of 1 μ l of purified PCR product, 1 μ l of primer, 1 μ l of 
BigDye, 1 μ l of Buffer BigDye and 6 μ l of H2O to a final volume of 10 μ l. The reaction 
is performed on Veriti Thermal Cycler (Applied Biosystems) and comprises 25 cycles 
of: denaturation step at 96°C for 10', annealing step at 50°C for 5' and extension step at 
60°C for 4'. 
 
 
 Sequence reaction purification 
A new purification step follows the sequencing reaction to eliminate primers and non-
incorporated fluorescent nucleotides that would interfere with reading on the automatic 
capillary sequencer. Different kits are used for purification depending on the amount of 
samples, single columns of DyeEx 2.0 Spin Kit (QIAGEN), and plates of 96 samples 
(CENTRISEP - Princeton Separations). Each kit is based on the same principle of 
chromatography for gel filtration, in which the molecules are separated on the basis of 
their molecular weight. Purification takes place through a first centrifugation step that 
removes the liquid in which the resin is stored and making the resin packed into a semi-
solid structure. The sequencing reaction is then transferred in the column with the resin 
and a second centrifugation step is performed. The resin retains the non-incorporated 
components of the sequencing reaction and the purified PCR product is eluted. 
 
 Sanger Sequencing with automatic capillary electrophoresis 
Once the sequencing product has been purified, it is loaded on the 16 capillaries 
automatic sequencer ABI 3130 or in the 24 capillaries automatic sequencer ABI 3500xL 
(Applied Biosystem). Within each capillary, each fluorescent nucleotide is 
electrophoretically separated using POP7 polymer. The polymer’s matrix separates 
fragments based on their size through the potential difference applied by the instrument 
to both ends of each capillary. As the single fluorescent nucleotide is scanned by the 
laser, the fluorochrome is excited releasing a fluorescent signal. The intensity and 
wavelength of the emitted light are captured and measured. The information regarding 
the color and type of ddNTP present at the end of each filament of different sizes is 
processed in a software. The information is thus integrated and transformed in color 
peaks, with areas proportional to the emission intensity. The classic electropherogram is 
thus formed. Raw sequencing data are analyzed through the Sequencing Analysis 
program (Applied Biosystem). The program also provides an overview of the quality of 
the experiment, while Mutation Surveyor software (SoftGenetics) is used for data 
analysis.  
3.2.5 Data Analysis 
 BaseSpace  
Sequencing run data can be processed through a wide range of open-source or 
commercial pipelines developed for Illumina data, or instantly can be transferred, 
analyzed, and stored securely in BaseSpace (Cloud or Onsite), the Illumina genomics 
computing environment. BaseSpace downstream data analysis includes alignment and 
variant detection, annotation, visualization, and interpretation. There is an initial 
Demultiplexing phase, that allows detection of clusters positions on the flow cell, 
needed to discriminate the samples; subsequently the following files are generated: 
 FASTQ_text files, which contain information on the order of 
bases in the sequence and reading quality for each 
nucleotide (Phred Quality Score_Q). 
 BAM_files are produced by compression of larger SAM 
files and contain information on alignment of a determined 
sample compared to a reference sequence and chromosome 
coordinates.  
 VCF_variant call files contain information on variants found 
in specific positions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Variant Studio 
 
All files generated by NextSeq 500 can be loaded on different analysis software to view 
the variants and the alignment files of the sequence products.  
One such software is Variant Studio, released by Illumina. 
[https://www.illumina.com/content/dam/illuminamarketing/documents/products/datashe
ets/datasheet_illumina_variantstudio_software.pdf]. The software allows to visualize 
quickly VCF files containing a set of information on the variants found, including gene, 
variant nomenclature at nucleotide and aminoacid level, the nomenclature based on 
dbSNP (if described), Sift and PolyPhen data, allelic frequency, variant frequency in the 
general population and in different populations, the quality of base call, the GQX, the 
number of reads, the identification of the transcript, exonic or intronic position, 
classification, coordinates of chromosomic position, if it is a conserved base, the 
associated pathology if described, links to Google Scholar, PubMed, UCSC Browser, 
ClinVar RS, ClinVar, OMIM, Orphanet, GeneReviews and many other useful  
information for the final evaluation of the variants found.  
 
 IGV  
Sequence raw data can be viewed through IGV (Integrative Genomics Viewer), a free 
software downloadable from the Broad Institute site. This interface graphically shows 
the sequence alignments and the reads (coverage and BAM files) of all sequenced 
genes, and provides information regarding all variants found (VCF files). The program 
gives a general idea on the quality of the experiment in toto; it allows to view all the 
regions not covered by sequencing, regions with little coverage or with low quality of 
reads. Through IGV we can estimate which regions need to be sequenced through 
Sanger sequencing to complete the analysis of entire coding regions. [Thorvaldsdóttir H 
et al.; 2013]. 
 
 
 
 Mutation Surveyor  
Exons with probably or definitely pathogenetic variants and those insufficiently covered 
or completely uncovered are analyzed by Sanger sequencing. Following PCR and 
classic sequencing reactions of the regions of interest, fragments are analyzed on 
automatic sequencers ABI3130 XL and ABI3500xL (Applied Biosystems); sequences 
obtained can then be analyzed with different programs, including Mutation Surveyor 
(SoftGenetics). Sequences are loaded on the program with the reference sequence 
(downloadable from GeneBank, in gbk format). Mutation Surveyor identifies the 
variants by comparing the physical differences between the electrophoretic peaks of the 
reference and of the test sample sequences [Dong C. et al.; 2013]. 
 
 Alamut 
A tools that helps us to understand the potential pathogenicity of a variant is Alamut, an 
in silico prediction software (Interactive Biosoftware). Alamut is an interactive software 
that allows to view the gene of interest and to have all the information about it; once the 
variant has been highlighted all information on the variant are obtained through links to 
all the online analysis databases. Very important is the evaluation on canonical and non-
canonical splicing sites performed by the software. It also provides the level of 
conservation of the nucleotide and amino acid in various species. It cannot, of course, 
replace an in vivo study of the variant, but it definitely helps to understand if the variant 
is to be taken into account [http://www.interactive-biosoftware.com/doc/alamut-
batch/1.7.0/EN/Alamut-Batch-1.7.0-User-Manual.pdf]. 
 
 
 
 
 
 
 
4. RESULTS 
In the present study we analyzed 134 patients, differently distributed among the various 
pathologies under investigation. In detail, 41 patients with anophthalmia, 
microphthalmia and Coloboma have been included in this study (Tab. 1). Of these, 12 
(29%) displayed variants in the analyzed genes (Tab. 2). Among 34 patients with 
CHARGE syndrome (Tab. 3), 19 (55%) displayed variants in the CHD7 gene (Tab. 4), 
while of 37 patients with Cornelia De Lange syndrome (Tab. 5), 7 (19%) showed 
variants in the associated genes (Tab. 6). Eight patients with Axenfeld-Rieger syndrome 
have been analyzed (Tab.7). Of these, 2 patients (25%) had mutations in two genes 
involved in the pathology (Tab. 8). Respectively 8 and 6 patients have syndromes 
associated to PAX2 and BCOR genes, with only one patient displaying a deletion in 
BCOR. 
 
Tab 1. Total MACs samples  
ID PAX6 SOX2 OTX2 VSX2 GDF6 SHH RAX OTHER 
GENES 
1 Neg Neg Neg Neg Neg Neg Neg Neg 
2 
Neg Neg Neg Neg Neg Neg Neg SMC3  
R521Q  
ex16 
3 
Neg Neg Neg Neg Neg Neg c.290-
4 
C>A 
Neg 
4 
Neg Neg c.97+12 
C>T 
Neg Neg Neg Neg Neg 
5 Neg Neg Neg Neg Neg Neg Neg Neg 
6 Neg Neg Neg Neg Neg Neg Neg Neg 
7 
Neg Neg Neg Neg Neg Neg Neg BMP4  
R211Q  
ex4 
8 Neg Neg Neg Neg Neg Neg Neg Neg 
9 Neg Neg Neg Neg Neg Neg Neg Neg 
10 Neg Neg Neg Neg Neg Neg Neg Neg 
11 Neg Neg Neg Neg Neg Neg Neg Neg 
12 
Neg Neg Neg Neg Neg Neg Neg STRA6 
Y18Tfs*54; 
F654X 
13 
Neg Neg Neg Neg Neg Neg Neg STRA6  
c.928-2  
A>G 
14 Neg Neg Neg Neg Neg Neg Neg Neg 
15 
Neg Neg Neg c.244delG 
p.L84S 
fs*57 
Neg Neg Neg Neg 
16 Neg Neg Neg Neg Neg Neg Neg Neg 
17 Neg Neg Neg Neg Neg Neg Neg Neg 
18 Neg Neg Neg Neg Neg Neg Neg Neg 
19 
Neg Neg Neg Neg c.1304C>T 
p.A435V 
Neg Neg Neg 
20 Neg Neg Neg Neg Neg Neg Neg Neg 
21 
Neg Neg Neg Neg Neg Neg Neg BCOR 
c.5041C>T 
p.R1681C 
22 Neg Neg Neg Neg Neg Neg Neg Neg 
23 Neg Neg Neg Neg Neg Neg Neg Neg 
24 Neg Neg Neg Neg Neg Neg Neg Neg 
25 
Neg Neg Neg Neg Neg Neg Neg BMP4  
c.979 G>A 
p.V327M 
26 Neg Neg Neg Neg Neg Neg Neg Neg 
27 Neg Neg Neg Neg Neg Neg Neg Neg 
28 
Neg Neg c.97+12 
C>T 
Neg  Neg Neg Neg 
29 
Neg Neg Neg Neg c.322 G>A 
p.A108T 
Neg Neg Neg 
30 Neg Neg Neg Neg Neg Neg Neg Neg 
31 Neg Neg Neg Neg Neg Neg Neg Neg 
32 Neg Neg Neg Neg Neg Neg Neg Neg 
33 Neg Neg Neg Neg Neg Neg Neg Neg 
34 Neg Neg Neg Neg Neg Neg Neg Neg 
35 Neg Neg Neg Neg Neg Neg Neg Neg 
36 Neg Neg Neg Neg Neg Neg Neg Neg 
37 Neg Neg Neg Neg Neg Neg Neg Neg 
38 Neg Neg Neg Neg Neg Neg Neg Neg 
39 Neg Neg Neg Neg Neg Neg Neg Neg 
40 Neg Neg Neg Neg Neg Neg Neg Neg 
41 Neg Neg Neg Neg Neg Neg Neg Neg 
 
   
 
 
 
 
 
 
Tab.2. Variants found in MACs genes 
 
 
 
Detailed variants identified in MAC patients: 
 
Missense mutations 
Six missense mutations (46%) have been found in patients with anophthalmia and 
microphthalmia (A/M) diagnosis. Two mutations in the GDF6 gene, c.322G>A 
(p.A108T) and c.1304C>T (p.A435V), fall respectively into the N-terminal and C-
terminal domains of the protein. For both variants, the small chemical-physical 
differences present in the aminoacids do not lead to drastic functional changes in the 
protein. The 4 remaining missense variants reported have been detected in additional 
genes of the MAC panel. The c.1562G>A (p.R521Q) mutation in the SMC3 gene may 
compromise the functionality of the protein as it falls into a functional region of the N-
terminal domain (RecF/RecN/SMC domain). SMC3 gene is normally associated to a 
Cornelia- like phenotype. The variant c.5041C>T (p.R1681C) in the BCOR gene could 
ID GENE EXON NUCLEOTIDE 
CHANGE 
AMINOACID 
CHANGE 
MUTATION 
TYPE 
2 SMC3 16 c.1562 G>A R521Q Missense 
3 
RAX Intr. 1 c.290-4C>A  Splicing 
Mutation? 
4 
OTX2 Intr. 
3b 
c.97+12 C>T  Splicing 
Mutation? 
7 BMP4 4 c.632 G>A R211Q Missense 
12 
STRA6  
 
c.52delT 
c.1961_1962 
Y18Tfs*54 
 F654X 
Deletion 
Nonsense 
13 
STRA6 Intr. 
14 
c.928-2 A>G  Splicing 
Mutation 
15 
VSX2 1 c.244 del G L84S fs*57 Frameshift 
deletion 
19 GDF6 2 c.1304 C>T A435V Missense 
21 BCOR 16 c.5041 C>T R1681C Missense 
25 BMP4 5 c.979 G>A V327M Missense 
28 
OTX2 Intr. 
3b 
c.97+12 C>T  Splicing 
Mutation? 
29 GDF6 1 c.322 G>A A108T Missense 
cause a functionality impairment of the polypeptidic chain, due to chemical-physical 
differences between the two aminoacids. The c.979G>A (p.V327M) mutation in the 
BMP4 gene falls into the C-terminal domain and is reported as deleterious or potentially 
pathogenetic in pathogenicity prediction databases. 
Splicing mutations 
The c.928-2A>G variant present in the STRA6 gene falls into the intron 14 acceptor 
splicing site. This change could lead to an abnormal splicing mechanism of the mRNA. 
The other two intronic variants detected, c.290-4C>A in the RAX gene and 
c.97+12C>T in the OTX2 gene, are nucleotide changes within the splicing regions, but 
their actual pathogenetic function is not known.  
Frameshift deletions 
The c.244delG (p.L84Sfs*57) deletion mutation in the VSX2 gene creates a reading 
frameshift from codon L84, resulting in a STOP codon 56 aminoacids downstream. 
Another deletion resulting in a frameshift, in particular a thymine at position c.52, has 
been found in patient N° 12 in the STRA6 gene.  
 
Nonsense mutation 
 
The only nonsense mutation found among the MAC genes patients has been detected in 
the STRA6 gene in patient N° 12. The variant is present in position c.1961_1962 and 
determines the modification of the phenylalanine codon with a stop codon. 
 
 
 
 
 
 
 
 
 
Tab. 3 Total samples with CHARGE Syndrome  
 
ID CHD7 
1 Neg 
2 Neg 
3 c.5241C>G 
p.Y1747X 
4 Del ex1 
5 c.5405-17G>A 
6 Neg 
7 c.2096G>A 
p.S699N 
8 c.5625T>C 
p.P1875P 
9 c.8994+35 
T>C 3'UTR 
10 Neg 
11 Neg 
12 Neg 
13 c.7282C>T 
p.R2428X 
14 c.2238+1G>A 
15 Neg 
16 Neg 
17 c.6103+8C>T  
c.3765 G>A, p.P1255P 
18 c.307T>A, p.S103T 
c.7682G>A, p.G2561E 
19 c.3004C>T, p.Q1002X 
20 c.6357C>A, p.D2119E 
21 c.6111C>T, p.P2037P 
22 Neg 
23 Neg 
24 c.5293-5313delGACTCAAGGTTAGTGCGAGCT 
25 c.197delT 
c.200 T>A, p.T67K 
26 Neg 
27 c.1480 C>T, p.R494X 
28 Neg 
29 Neg 
30 ex23-4C>T 
31 c.307T>A, p.S103T 
32 c.6850 C>T, p.R2284X 
33 Neg 
34 Neg 
Tab. 4 Variants found in CHD7 gene 
 
ID GENE EXON NUCLEOTIDE 
CHANGE 
AMINOACID 
CHANGE 
MUTATION 
TYPE 
3 CHD7 24 c.5241C>G Y1747X Nonsense 
4 CHD7 1   Deletion 
5 CHD7 
Intr. 
25 
c.5405-17 G>A  
Splicing 
Muatation? 
7 CHD7 3 c.2096 G>A S699N Splicing Muation 
8 CHD7 28 c.5625 T>C P1875P Synonymous 
9 CHD7 
Intr. 
38 
c.8994+35 T>C 3'UTR  Splicing Mutation 
13 CHD7 34 c.7282 C>T R2428X Nonsense 
14 CHD7 Intr. 4 c.2238+1G>A  Splicing Mutation 
17 CHD7 
Intr. 
30 
c.6103+8C>T   Splicing Mutation 
15 c.3765 G>A  P1255P Synonymous 
18 CHD7 
35 c.7682 G>A G2561E Missense 
2 c.307 T>A S103T Missense 
19 CHD7 12 c.3004 C>T Q1002X Nonsense 
20 CHD7 31 c.6357 C>A D2119E Missense 
21 CHD7 31 c.6111 C>T P2037P Synonymous 
24 CHD7 24 c.5293-5300 +13 del  
Deletion 
frameshift 
25 CHD7 2 
c.197delT  
 
p.L66Rfs*17 
 
 
Deletion  
c.200 T>A T67K Missense 
27 CHD7 2 c.1480 C>T R494X Nonsense 
30 CHD7 
Intr. 
22 
c.5051 -4C>T  Splicing Mutation 
31 CHD7 2 c.307 T>A S103T Missense 
32 CHD7 32 c.6850 C>T R2284X Nonsense 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detailed variants identified in CHARGE patients: 
 
Missense mutations 
Among the 5 missense variants (22%) in the CHD7 gene, the detected variant 
c.307T>A (p.S103T) in two patients is potentially deleterious for the functionality of 
the protein according to the SIFT and PolyPhen genomic databases.  
Stop mutations 
Stop (nonsense) mutations in our study represent the 22% of the total mutations in the 
CHD7 gene and are located in different exons (2, 12, 24, 32, 34). The nucleotide 
changes leading to the formation of STOP codons could cause transcript degradation to 
avoid the formation of truncated proteins  trough the mechanism of Nonsense Mediated 
Decay (NMD). The nonsense-mediated mRNA decay (NMD) pathway is well known as 
a translation-coupled quality control system that recognizes and degrades aberrant 
mRNAs with truncated open reading frames (ORF) due to the presence of a premature 
termination codon (PTC) [Schweingruber C. et al.; 2013] 
.Splicing mutations 
Five variants have been reported in non-coding regions, specifically involved in the 
splicing mechanism, in the CHD7 gene. In particular, the c.2238+1G>A variant in 
intron 4, could cause an anomalous mRNA formation. Also, the c.2096G>A (p.S699N) 
nucleotide change in the coding portion of exon 3 involves a specific sequence 
implicated in splicing.  
Deletions 
The large 13bp deletion (c.5293-5300+13del) found in patient N°24 involves the exon-
intron 24 boundary, eliminating the whole region involved in splicing. A second 
deletion, c.197delT (p.L66Rfs*17), was found in exon 2 in patient N°25; while a third 
deletion has been detected in a non-coding, but potentially regulatory, region exon 1 of 
the CHD7 gene. 
Synonymous mutations 
Although synonymous mutations do not cause aminoacid changes, the 3 synonymous 
mutations detected, c.5625T>C (p.P1875P), c.3765G>A (p.P1255P) and c.6111C>T 
(p.P2037P), could compromise the functionality of the splicing mechanism due to the 
specific nucleotide changes involved. 
3'UTR variant  
The c.8994+35T>C nucleotide change in the 3'UTR of the CHD7 gene could cause an 
anomalous maturation mechanism of mRNA, as it involves a sequence dedicated to the 
recognition of specific proteins that constitute the complex spliceosome machinery. 
 
 
 
 
 
 
 
 
 
 
Tab. 5 Total samples with Cornelia De Lange syndrome  
ID NIPBL SMC3 SMC1A HDAC8 RAD21 OTHER 
GENES 
1 Neg Neg Neg Neg Neg Neg 
2 Neg Neg Neg Neg Neg Neg 
3 Neg Neg Neg Neg Neg Neg 
4 
c.535G>A 
p.A179T 
Neg Neg Neg  Neg 
5 
Neg Neg Neg Neg c.1635delA 
p.G547fs*65 
Neg 
6 Neg Neg Neg Neg Neg Neg 
7 Neg Neg Neg Neg Neg Neg 
8 Neg Neg Neg Neg Neg Neg 
9 c.6109-3T>C Neg Neg Neg Neg Neg 
10 Neg Neg Neg Neg Neg Neg 
11 Neg Neg Neg Neg Neg Neg 
12 Neg Neg Neg Neg Neg Neg 
13 Neg Neg Neg Neg Neg Neg 
14 Neg Neg Neg Neg Neg Neg 
15 
c.6620 T>C 
p.M2207T 
Neg Neg Neg Neg Neg 
16 Neg Neg Neg Neg Neg Neg 
17 Neg Neg Neg Neg Neg neg  
18 Neg Neg Neg Neg Neg Neg 
19 Neg Neg Neg Neg Neg Neg 
20 Neg Neg Neg Neg Neg Neg 
21 
c.781T>G 
p.S261A 
Neg Neg Neg Neg Neg 
22 Neg Neg Neg Neg Neg Neg 
23 Neg Neg Neg Neg Neg Neg 
24 Neg Neg Neg Neg Neg Neg 
25 Neg Neg Neg Neg Neg Neg 
26 Neg Neg Neg Neg Neg Neg 
27 Neg Neg Neg Neg Neg Neg 
28 Neg Neg Neg Neg Neg Neg 
29 
c.240dupA 
p.D81fs*2 
Neg Neg Neg Neg Neg 
30 Neg Neg Neg Neg Neg Neg 
31 Neg Neg Neg Neg Neg Neg 
32 Neg Neg Neg Neg Neg Neg 
33 Neg Neg Neg Neg Neg Neg 
34 Neg Neg Neg Neg Neg Neg 
35 
Neg Neg Neg Neg Neg BCOR 
c.190A>G 
p.I64V 
36 Neg Neg Neg Neg Neg Neg 
37 Neg Neg Neg Neg Neg Neg 
  
Tab. 6 Variants found in Cornelia de Lange syndrome  
 
ID GENE EXON NUCLEOTIDE 
CHANGE 
AMINOACID 
CHANGE 
MUTATION 
TYPE 
4 NIPBL 2 c.535G>A A179T Missense 
5 
RAD21 13 c.1635delA G547fs*65 Deletion 
frameshift 
9 NIPBL Intr. 34 c.6109-3 T>C   
15 NIPBL 39 c.6620 T>C M2207T Missense 
21 NIPBL 8 c.781T>G  S261A Missense 
29 
NIPBL 4 c.240dupA D81fs*2 Insertion 
frameshift 
35 BCOR 5 c.190A>G I64V Missense 
 
 
Detailed variants identified in Cornelia de Lange patients: 
 
Missense mutations 
Four missense mutations (57%) have been found in patients with Cornelia De Lange, 3 
of which are present in the NIPBL gene. In particular, the c.6620T>C (p.M2207T) 
mutation in the ARM like fold domain of the protein is reported as a possible causative 
mutation for Cornelia de Lange in pathogenicity prediction databases. The 4th missense 
variant reported, c.190A>G (p.I64V), was found in the BCOR gene, which is not 
directly involved in the syndrome but is included in the panel. 
Deletions 
The only deletion found is in the RAD21 gene. This deletion, c.1635delA 
(p.G547fs*65), determines a frameshift that leads to the formation of a STOP codon 64 
aminoacids downstream.  
 
 
 
Insertion 
The c.240dupA (p.D81fs*2) insertion mutation found in exon 4 of the NIPBL gene is a 
duplication of an adenine causing a frameshift, which results in the formation of a stop 
mutation in the following codon. 
Intronic variant 
The c.6109-3T>C intronic variant detected in the NIPBL gene is located in the splicing 
region of exon 35. In silico predictions studies performed through pathogenicity 
prediction databases gave it as a benign variant. 
 
 
          
          Tab. 7 Total samples with Axenfeld-Rieger syndrome 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
Tab. 8 Variants found in Axenfeld-Rieger syndrome 
 
 
 
ID PITX2 FOXC1 
1 
Neg 775C>T 
p.L86F 
2 
c.355 C>T 
p.Q119X 
Neg 
3 Neg Neg 
4 Neg Neg 
5 Neg Neg 
6 Neg Neg 
7 Neg Neg 
8 Neg Neg 
ID GENE EXON NUCLEOTIDE 
CHANGE 
AMINO ACID 
CHANGE 
MUTATION 
TYPE 
1 PITX2 6 c.355 C>T Q119X Nonsense 
2 FOXC1 1 c.256 C>T L86F Missense 
The two  mutations found  in patients with Axenfeld-Rieger syndrome involve both 
genes associated to the disease. The c.355C>T (p.Q119X) mutation in the PITX2 gene 
introduces a stop codon in exon 6. The c.256C>T (p.L86F) mutation in the FOXC1 
gene is a missense mutation which, from in silico prediction studies, appears as a 
causative mutation of the disease as it falls into the functional fork head domain, 
necessary for DNA binding. In the 8 patients analyzed for renal papilloma syndrome, no 
PAX2 variants have been detected, while among the 6 patients studied for Lenz 
microphthalmia, one patient presented a deletion in the BCOR gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
This work is based on the development of a new molecular method that allows the 
analysis of diseases that involve many genes. The introduction of Next Generation 
Sequencing has been useful for the analysis of microphthalmia, anophthalmia, 
coloboma and associated syndromes, as it gives the possibility to evaluate large 
genomic regions reducing costs and working times. Actually, the possibility to obtain a 
a lot of information on the mutational state of the genes involved in eye development in 
relatively short timings, the diagnosis for A/M is definitely more exhaustive. Genotype-
phenotype correlation studies can now be taken into account in the clinical evaluation. 
One of the main advances with NGS, concerning the molecular diagnosis, is the 
possibility to create panel of genes specific for different pathologies. In this view, 
molecular diagnosis of MACs became possible after the identification, by searching the 
literature, of the many genes involved in the pathogenic pathway. Following this, the 
use of DesignStudio, provided by Illumina, enabled the development of an appropriate 
panel comprising the genes of interest. The software helps the operator in the choice and 
elaboration of the amplicons to sequence. With the software help several specific probes 
encompassing the target regions thus designed. The sequencing method used by the 
NextSeq 500 system (Illumina) is the Sequencing By Synthesis (SBS),  with the use of 
the Nextera Rapid Capture Custom Enrichment kit. Among the parameters evaluated by 
the software directly installed on the instrument, the Quality Score, which represents the 
probability that a base is correctly called, and the percentage of "Clusters Passing 
Filter", representing the percentage of clusters generated that will be used for the 
sequencing, are the most important parameters. About 2 Gb of genomic information 
obtained from the experiment are available through BaseSpace and Variant Studio 
software; the raw sequencing data are displayed through the IGV software. Each variant 
found, compared to a genomic reference sequence, has been also evaluated by Sanger 
sequencing. The traditional method allowed us to confirm the validity of the data 
obtained with next generation sequencing. The amplicons with a poor reading quality on 
IGV, have also been analyzed with the classical Sanger sequencing. With the analysis 
softwares provided by Illumina for NextSeq and the online genomic databases, it was 
possible to assign a meaning to the many variants found, although in some cases purely 
theoretical. In the present study, NGS allowed us to analyze several genes for a given 
patient and to identify variants both in genomic regions directly involved in the 
pathogenesis of anophthalmia, microphthalmia and coloboma, both in genes not directly 
implicated in syndromic or isolated MACs. This feature allows us to understand at a 
molecular level many of those phenotypes that are shaded, atypical and not perfectly 
defined in a specific syndrome. In this regard, the continuous interaction with the 
referring physicians has been fundamental in our study. The results of the molecular 
analyses have always been evaluated in team, in some instances confirming the clinical 
suspect, in others calling in question the clinical signs and reevaluating the patient and 
the family members at a clinical level. 
Tab.9 Pathogenicity predict ions in variants of  MACs genes 
 
 
 
 
 
 
 
Mutations in GDF6 usually lead to the manifestation of coloboma forms and bone 
malformations during development. The A435V and A108T variants found in the 
present study, have a very low frequency in the global population and their 
pathogenicity was discordant after analysis with two prediction softwares. Once the 
variants have been found, they have been loaded on Alamut software (Interactive 
Biosoftware) to define a pathogenicity prediction. Alamut retrieves information on 
aminoacid substitution from two sites: SIFT (Sorting Tolerant From Intolerance) and 
Mutation Taster; they are both based on algorithms able to elaborate the aminoacid 
position within the polypeptide chain under study. The position of the mutated 
aminoacid is compared to various species in order to determine its conservation during 
evolution. The higher the conservation of that aminoacid, the higher will be its 
importance in the protein function [Kumar P. et al.; 2009]. From this assumption the 
pathogenicity of the mutation is determined in silico (Tab. 9). 
GENE MUTATION  SIFT MUTATION TASTER 
SMC3 R521Q - Harmful - 
BMP4 R211Q - - - 
GDF6 A435V 0% Tolerated Cause of disease 
BCOR R1681C - Harmful Cause of disease  
BMP4 V327M - Harmful Cause of disease  
GDF6 A108T 0% Tolerated Cause of disease  
The other missense mutations found in MAC patients, never described in the literature, 
are very rare and have potentially harmful effects on the phenotype. For some of these 
(SMC3 R521Q, BMP4 R211Q) it was possible to perform familiar studies and to follow 
the mutation segregation (Fig.6).  
 
 
 
Fig. 6 Familiar studies for the variants R521Q in the SMC3 gene and R211Q in the BMP4 gene  
 
Familial studies help us to elucidate if that variant has indeed a phenotypic effect, as the 
transmitted variant should have no meaning unless the carrier parent has also 
phenotypic features resembling the probands disease. Moreover with dominant 
pathologies, incomplete penetrance and variable expression have to be taken into 
account as possible mechanism. Family analysis also enables the formulation of the 
recurrence risk of the disease in subsequent generations.  
In addition to the missense variants, accounting for 46% of mutations in our cohort of 
A/M patients, other variants include splicing mutations, deletions and intronic variants. 
Regarding the splicing mutations, the c.928-2A>G change in intron 14 of the STRA6 
gene, could lead the exclusion of exon 15 from the transcript during the editing phase of 
mRNA.  
Mutations in this gene are implicated in the Matthew-Wood syndrome (Syndromic 
microphthalmia, type 9), a rare clinical condition whose main features include severe 
anophthalmia or microphthalmia and hypoplasia or pulmonary aplasia. As this is a 
recessive condition, the second causative mutation was searched, although with no 
success. Regarding the STRA6 gene, we found two distinct pathogenic variants 
(Y18Tfs*54 and F654X) in a single patient (patient N°12). The first variant causes a 
frameshift that introduces a STOP codon 55 aminoacids downstream, while the second 
is a nonsense variant, also generating a premature interruption of the sequence. For this 
patient, for which both parents were available, it was also possible to study the 
segregation of the mutations and to confirm the compound heterozygosity as each 
parent had one of the two mutations. During the genetic counseling, the couple was 
informed of their recurrence risk and of the possibility,  in case of a future pregnancy, to 
monitor the state of the fetus at the molecular level.  
Another deletion, L84Sfs*57 has been detected in the VSX2 gene. This deletion causes 
a frameshift  which introduces a STOP codon 56 aminoacids downstream. The 
premature interruption of the mRNA could lead to mRNA degradation, to avoid the 
translation of an inactive truncated protein (NMD, nonsense mediated decay). Some 
variants reported in the study include intronic nucleotide changes. These intronic 
mutations have been investigated because they are near to coding sequences and are 
probably involved in the splicing process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our casuistry of 34 patients with CHARGE syndrome, 19 patients (56%) showed 
variants in the CHD7 gene (Fig. 7). The gene encodes for a protein involved in gene 
expression regulation and, when mutated, is responsible for a wide range of severe 
phenotypes. The variants found reflect a random and homogeneous distribution within 
the gene. 
 
 
Fig.7 CHD7 gene 
 
The mutations reported in the study include missense and nonsense variants, deletions, 
synonymous mutations and intronic variants involved in the spiicing process. The 
pathogenicity prediction for the missense mutations was made through SIFT and 
Mutation Taster, which gave us the possibility to compare modified aminoacids in the 
mutated sequence (Tab. 10). 
 
 
Tab. 10. Pathogenicity prediction for the variants present in the CHD7 gene 
 
 
 
 
 
 
 
 
 
 
 
 
GENE MUTATION  SIFT MUTATION TASTER 
CHD7 S699N - Tolerated Cause of disease 
CHD7 G2561E - Tolerated Cause of disease 
CHD7 S103T 1% Harmful Cause of disease 
CHD7 D2119E - Tolerated Cause of disease 
CHD7 T67K - Tolerated Cause of disease 
Most missense mutations, which accounted for 24% of the total mutations in CHD7, 
have not been described in the literature and their frequency is not predictable because 
they have never been found in the population. The discrepancy given by the softwares 
regarding pathogenicity prediction suggests the need of in vivo studies of the protein. 
The available data to study these variants include: Alamut, which is mainly used for in 
silico pathogenicity prediction and collects all information on the variant from the 
databases connected to it (SIFT, Mutation Taster, population frequency/1000 genomes, 
species conservation, scientific literature); PubMed and the scientific literature linked to 
the variant or to the gene involved; and familial studies. Variants introducing a STOP 
codon, hence providing an incomplete transcript, were found in exons 2, 12, 24, 32, 34. 
Even for the STOP mutations found we couldn’t find any feedback from the literature. 
In two patients, we found variants interfering with the splicing process, such as the 
intronic variant c.2238+1G>A or the exon 3 change c.2096G>A (p.S699N), where the 
substitution of a guanine with an adenine in the coding region likely influences the 
splicing reaction. Also the c.8994+35T>C variant at the 3'UTR could be considered as 
potentially harmful for the general mechanism of mRNA formation. Although limited, 
our casuistry of CHD7 mutations showed a wide range of mutations. For example 
deletions in exons 2 and exon 24 were detected. In this latter case the deletion was 
located at position c.5293-5300+13 and involves the last nucleotides of exon 24 and the 
first of intron 24. This important deletion could result in a frameshift mutation affecting 
the reading frame in the following exon or have implications on the splicing process. 
The other deletion reported, c.197delT (p.L66Rfs*17), involves exon 2 in patient N°25, 
and results in a frameshift which introduces a STOP codon 17 aminoacids downstream. 
However, in this patient we also found the c.200T>A (p.T67K) variant. A mutational 
hotspot at this site for the gene could thus be suggested. In order to investigate the 
segregation of the two mutations, it was possible to carry out a familial study. Both 
parents were negative determining the de novo nature of the mutations. Hence, it was 
not possible to determine if the disposition of the variants was in cis or in trans.  A 184 
Kb deletion including both a part of the RAB2 gene and a part of the CHD7 gene was 
highlighted in patient N°4. The region involved in our gene of interest includes the non-
coding exon 1 of CHD7, which is far from the ATG site, but probably important as a 
regulatory region. 
It has been very interesting the study of synonymous mutations such as c.5625T>C 
(p.P1875P) (Fig.8), c.3765G>A (p.P1255P) and c.6111C>T (p.P2037P). Although their 
nucleotide changes do not cause an alteration in the translated aminoacid, they could 
cause changes in the splicing process. This was suggested by the Alamut software 
(Fig.9), which indicates the effect of a mutation on the success of splicing. 
 
 
Fig. 8. Sequence of the c.5625T>C (p.P1875P) variant 
 
Fig. 9. Splicing site variation due to c.5625T>C (p.P1875P)  mutation  
 
 
 
 
Our interest for these variants arose because they have never been found in the general 
population and are considered rare variants.  
Among all patients analyzed with Cornelia De Lange syndrome, we found 7 variants 
(19%) (Tab. 11). Of these variants, 71% are located in NIPBL gene, in accordance with  
literature data [Deardorff M.A. et al., 2012], as NIPBL is the most frequently mutated 
gene in patients with Cornelia de Lange syndrome. Of the mutations found for these 
gene, 57% were missense mutations for which it was possible to determine a 
pathogenicity risk. In particular the c.781T>G (p.S261A) and c.6620T>C (p.M2207T) 
mutations in the NIPBL gene have been associated to the development of the disease by 
Mutation Taster and the latter (M2207T) has never been described in the literature. In 
addition, we found an adenine insertion, resulting in the c.240dupA (D81fs*2a) 
frameshift mutation, and an intronic variant, c.6109-3T>C, located in the splicing 
region. The c.1635delA (p.G547fs*65) mutation in the RAD21 gene was the only 
deletion found. This deletion causes a frameshift and introduces a STOP codon 64 
aminoacids downstream. The BCOR gene has also been included in the panel of genes 
associated to A/M syndromic diseases. This allowed us to identify the c.190A>G 
(p.I64V) variant, reported as harmful according to in silico softwares and has never 
been described in the literature. 
 
Tab. 11. Pathogenicity prediction of variants associated to Cornelia De Lange syndrome  
 
 
 
 
 
 
 
A total of 8 patients have been analyzed for Axenfeld-Rieger syndrome. In a first 
patient we found the c.355C>T (p.Q119X) mutation in the PITX2 gene, determining the 
formation of a STOP codon in exon 6. In the second patient, the c.256C>T (p.L86F) 
variant was detected in the FOXC1 gene. This variant was reported as pathogenic by 
prediction softwares as it falls in a functional domain of the protein, the fork head 
domain, which is required to bind target regions of DNA (Tab.12). 
GENE MUTATION  SIFT MUTATION TASTER 
NIPBL A179T - Tolerated Polymorphism 
NIPBL M2207T - Harmful Cause of disease 
NIPBL S261A 1% Tolerated Cause of disease 
BCOR I64V - Harmful Polymorphism 
     
Tab. 12. Pathogenicity prediction of the variant associated to Axenfeld-Rieger syndrome 
 
 
 
 
 
 
Respectively 8 and 6 patients were studied for PAX2 and BCOR genes. Of these, only 
one patient exhibits a deletion in the BCOR gene. The deletion has been detected by 
CGH array (Agilent platform) and spans 6.9 Mb (104 probes) from position 32.967.915 
(Xp21.1) to position 39.913.316 (Xp11.4). This genomic region contains several genes 
including DMD (Dystrophin), XK (Kell blood group precursor), CYBB (Cytochrome b-
245, beta polypeptide), RPGR (Retinitis pigmentosa GTPase regulator), OTC 
(Ornithine transcarbamylase), TSPAN7 (Tetraspanin 7) and  BCOR (BCL6 corepressor). 
Many of the data found in this study highlight the importance to complement NGS 
technique with other methods, such as CGH array and mRNA studies. This is true for 
example for the detection of large deletions that would go unnoticed through Next 
Generation Sequencing, except for particular cases such as deletions of X chromosome 
in males, or is also true for understanding the path of mRNA transcripts with STOP 
mutations, for which mRNA studies are essential.  
Surely the methodology we used to study MACs and their associated syndromes can 
help in the classification and definition of those phenotypes that are still difficult to 
classify, since all the potential variants that can be identified provide a wider 
understanding of the pathology. Also, such methodological approach with a broader 
spectrum of analysis can be very challenging and stimulating both for physicians and 
molecular geneticists, with the ultimate goal for both specialists to work in collaboration 
to find a link between the phenotypes described by the clinician and the many variants 
still to be identified by the geneticist. 
 
 
 
 
 
GENE MUTATION  SIFT MUTATION TASTER 
FOXC1 L86F - Harmful Cause of disease 
6. CONCLUSIONS 
 
Children with isolated or syndromic ocular malformations (MAC: microphthalmia, 
anophthalmia and coloboma) constitute a group of patients with a high degree of 
heterogeneity, both at phenotypic and genetic levels. Currently, national or international 
shared guidelines have yet to be defined and a phenotypic or genetic classification of 
the disease is still missing. Similarly to what happens for most rare diseases, the 
diagnostic and care management of children with ocular syndromes suffers heavily from 
the absence of strong scientific knowledge that would help in the development of shared 
guidelines, mainly because the phenotypic heterogeneity of these diseases is massive. 
The situation is slightly different for those patients with a more defined clinical 
phenotype, such as CHARGE, Cornelia de Lange and Axenfield-Rieger syndromes; 
however, we also have patients with Cornelia-Like phenotypes, and these patients will 
also show shaded clinical pictures compared to the classical forms.  
In recent years, the study of isolated and syndromic MACs has had a remarkable 
development. The introduction of Next Generation Sequencing as a diagnostic tool is 
expanding enormously our knowledge on the molecular bases of pathogenesis. Our 
study also demonstrates that it is a crucial step to accompany functional studies to the 
potential amount of data that we are now able to acquire by this new technique.  
Indeed, NGS is revolutionizing the approach of genetic studies, both for mendelian and 
complex diseases. Informatic tools can help in the definition of the pathogenicity 
prediction but will never replace an in vivo study. One of the goals for the future wil l be 
to create a multidisciplinary clinical pathway in oculistics, rare diseases and medical 
genetics to perform genotype-phenotype correlation studies with the aim of establishing 
a classification for isolated and syndromic MACs.  
In addition, with the design of larger panels and the rapid evolution of exome 
sequencing for the identification of new genes involved in different pathologies, it will 
be possible to have deeper insights on the phenotype-genotype correlation of several 
diseases. 
This will lead to a more comprehensive picture of the genetic and genomic bases of 
diseases that will eventually lead to a more specific diagnostic and care management. 
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